Patient demographics, laboratory values, and leukemia classifications
| . | TLP only . | TLP of TLP to RCE . | RCE of TLP to RCE . | RCE only . |
|---|---|---|---|---|
| Total number of patients | 61 | 11 | 5 | |
| Total number of procedures (including repeats) | 76 | 12 | 14 | 6 |
| Mean number of procedures per patient | 1.2∗∗∗ | 2.4∗∗∗ | 1.2 | |
| Age, y | ||||
| Median | 63 | 69 | 73 | |
| Range | 21-92 | 57-82 | 72-78 | |
| Sex | ||||
| Female | 28 | 5 | 2 | |
| Male | 33 | 6 | 3 | |
| Sex ratio (female-to-male) | 0.8 | 0.8 | 0.7 | |
| Received hydroxyurea, % (n) | 100 | 80 (9) | 60 (3) | |
| 30-day survival % (n) | 80 (46) | 70†(8) | 100 | |
| Preprocedure WBC, × 103/μL | ||||
| Median | 153 | 197 | 156 | 217 |
| Range | 59.3-485 | 86.5-294 | 83.2-221 | 196-386 |
| Postprocedure WBC, × 103/μL | ||||
| Median | 72.5∗∗∗∗ | 147 | 83.0∗∗∗ | 134 |
| Range | 23.3-239 | 76.2-204 | 55.0-140 | 105-167 |
| WBCreduction, % | ||||
| Median | 45.6 | 27.1 | 45.9 | 46.5 |
| Range | 6.10-79.7 | 5.27-45.1 | 23.0-61.1 | 26.5-56.7 |
| Preprocedure hematocrit, % | ||||
| Median | 25‡∗∗ | 23§∗∗ | 25 | 23 |
| Range | 15-44 | 16-26 | 19-26 | 22-26 |
| Postprocedure hematocrit, % | ||||
| Median | 24 | 23 | 25 | 28 |
| Range | 15-44 | 17-27 | 19-28 | 24-30 |
| Blood volumes processed | ||||
| Median | 2.0||∗∗∗∗ | 2.1∗∗∗∗ | 1.2∗∗∗∗ | 1.2∗∗∗∗ |
| Range | 0.9-3.2 | 0.8-3.6 | 0.9-1.7 | 0.8-1.5 |
| pRBC units used | ||||
| Median | 8 | 6 | ||
| Range | 4-12 | 6-8 | ||
| Leukemia classification | ||||
| AML NOS, % (n) | 60 (37) | 27 (3) | 20 (1) | |
| AML with monocytic or myelomonocytic differentiation, % (n) | 30 (18)∗ | 60 (7)∗ | 60 (3)∗ | |
| B-ALL, % (n) | 8 (5) | 0 | 20 (1) | |
| T-ALL, % (n) | 2 (1) | 0 | 0 | |
| MPAL, % (n) | 0 | 9 (1) | 0 | |
| History of CML, % (n) | 1 (1) | 9 (1) | 0 | |
| . | TLP only . | TLP of TLP to RCE . | RCE of TLP to RCE . | RCE only . |
|---|---|---|---|---|
| Total number of patients | 61 | 11 | 5 | |
| Total number of procedures (including repeats) | 76 | 12 | 14 | 6 |
| Mean number of procedures per patient | 1.2∗∗∗ | 2.4∗∗∗ | 1.2 | |
| Age, y | ||||
| Median | 63 | 69 | 73 | |
| Range | 21-92 | 57-82 | 72-78 | |
| Sex | ||||
| Female | 28 | 5 | 2 | |
| Male | 33 | 6 | 3 | |
| Sex ratio (female-to-male) | 0.8 | 0.8 | 0.7 | |
| Received hydroxyurea, % (n) | 100 | 80 (9) | 60 (3) | |
| 30-day survival % (n) | 80 (46) | 70†(8) | 100 | |
| Preprocedure WBC, × 103/μL | ||||
| Median | 153 | 197 | 156 | 217 |
| Range | 59.3-485 | 86.5-294 | 83.2-221 | 196-386 |
| Postprocedure WBC, × 103/μL | ||||
| Median | 72.5∗∗∗∗ | 147 | 83.0∗∗∗ | 134 |
| Range | 23.3-239 | 76.2-204 | 55.0-140 | 105-167 |
| WBCreduction, % | ||||
| Median | 45.6 | 27.1 | 45.9 | 46.5 |
| Range | 6.10-79.7 | 5.27-45.1 | 23.0-61.1 | 26.5-56.7 |
| Preprocedure hematocrit, % | ||||
| Median | 25‡∗∗ | 23§∗∗ | 25 | 23 |
| Range | 15-44 | 16-26 | 19-26 | 22-26 |
| Postprocedure hematocrit, % | ||||
| Median | 24 | 23 | 25 | 28 |
| Range | 15-44 | 17-27 | 19-28 | 24-30 |
| Blood volumes processed | ||||
| Median | 2.0||∗∗∗∗ | 2.1∗∗∗∗ | 1.2∗∗∗∗ | 1.2∗∗∗∗ |
| Range | 0.9-3.2 | 0.8-3.6 | 0.9-1.7 | 0.8-1.5 |
| pRBC units used | ||||
| Median | 8 | 6 | ||
| Range | 4-12 | 6-8 | ||
| Leukemia classification | ||||
| AML NOS, % (n) | 60 (37) | 27 (3) | 20 (1) | |
| AML with monocytic or myelomonocytic differentiation, % (n) | 30 (18)∗ | 60 (7)∗ | 60 (3)∗ | |
| B-ALL, % (n) | 8 (5) | 0 | 20 (1) | |
| T-ALL, % (n) | 2 (1) | 0 | 0 | |
| MPAL, % (n) | 0 | 9 (1) | 0 | |
| History of CML, % (n) | 1 (1) | 9 (1) | 0 | |
Leukemia classification based on most recent preprocedure analysis of peripheral blood by flow cytometry or bone marrow biopsy. AML NOS, acute myeloid leukemia, not otherwise specified; B-ALL, B-acute lymphoblastic leukemia; T-ALL, T-acute lymphoblastic leukemia; MPAL, mixed phenotype acute leukemia; CML, chronic myeloid leukemia.
Myelomonocytic leukemia classification: ∗P = .04, Fisher exact test. Median and range for pre- and postprocedure laboratory values. ‡Three patients and §1 patient were excluded because the instrument reading was flagged as inaccurate. †One patient was excluded due to being lost to follow-up. ||Two patients were excluded as data were unavailable. Number of procedures: ∗∗∗P < .0001 Mann-Whitney test comparing both TLP groups. Postprocedure WBC count: ∗∗∗P = .0019 Mann-Whitney test comparing between the paired TLP and RCE, ∗∗∗∗P < .0002 Mann-Whitney test comparing both TLP groups. Preprocedure hematocrit: ∗∗P < .04 Mann-Whitney comparing both TLP groups. Blood volume processed: ∗∗∗∗P < .0001 analysis of variance (ANOVA) comparing among all groups followed by a Wilcoxon rank test comparing the paired TLP to RCE groups, P = .0098.